Quoin Pharmaceuticals, Ltd. (QNRX) Financial Statements
Industry: Pharmaceutical Preparations
In fiscal 2025, Quoin Pharmaceuticals reported revenue of $0. Net income was -$15.8M, or -$14.80 per diluted share. Operating activities generated -$13.5M of cash. At fiscal year end, Quoin Pharmaceuticals held $20.4M in total assets against $7.3M in total liabilities, including $3.8M of cash and equivalents.
Open the full interactive Quoin Pharmaceuticals financials → Quarterly statements, key ratios, valuation history and price charts.
Quoin Pharmaceuticals Key Stats
| Share Price | $4.15 |
|---|---|
| Market Cap | $11.8M |
| 52-Week Range | $3.25 – $22.30 |
| Shares Outstanding | 2.8 million (basic, 2026 Q2) |
Quoin Pharmaceuticals Income Statement
| FY 2022 | FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 |
| Pre-Tax Income | -$9.4M | -$8.7M | -$9.0M | -$15.8M |
| Net Income | -$9.4M | -$8.7M | -$9.0M | -$15.8M |
| Diluted EPS | -$1638.00 | -$337.40 | -$66.85 | -$14.80 |
Quoin Pharmaceuticals Quarterly Results
| 2025 Q3 | 2025 Q4 | 2026 Q1 | 2026 Q2 | |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 |
| Net Income | -$3.9M | -$4.3M | -$5.0M | -$5.4M |
| Diluted EPS | -$6.71 | -$4.07 | -$1.77 | -$1.90 |
Quoin Pharmaceuticals Balance Sheet
| FY 2022 | FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|---|
| Cash & Equivalents | $2.9M | $2.4M | $3.6M | $3.8M |
| Current Assets | $13.4M | $11.3M | $14.9M | $20.0M |
| Total Assets | $14.5M | $12.2M | $15.7M | $20.4M |
| Current Liabilities | $3.5M | $3.6M | $4.2M | $5.5M |
| Total Liabilities | $7.1M | $6.5M | $6.5M | $7.3M |
| Shareholders' Equity | $7.4M | $5.7M | $9.2M | $13.1M |
Quoin Pharmaceuticals Cash Flow Statement
| FY 2022 | FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|---|
| Cash From Operations | -$8.5M | -$7.9M | -$7.9M | -$13.5M |
| Cash From Investing | -$10.1M | $2.2M | -$1.9M | -$4.3M |
| Cash From Financing | $14.0M | $5.2M | $11.0M | $18.0M |
Figures from Quoin Pharmaceuticals' 10-K and 10-Q filings with the SEC, as of 2026-10-14. Fiscal years follow the company's own reporting calendar. EPS and share counts are adjusted for later stock splits. See the full Quoin Pharmaceuticals financials page for every line item.
Quoin Pharmaceuticals Company Profile
| Ticker | QNRX |
|---|---|
| Exchange | Nasdaq |
| Industry | Pharmaceutical Preparations |
| Headquarters | Ashburn, Virginia |
| SEC Filer Category | Non-accelerated filer, smaller reporting company |
| SEC CIK | 0001671502 |
Frequently Asked Questions
What was Quoin Pharmaceuticals' revenue in fiscal 2025?
Quoin Pharmaceuticals (QNRX) reported revenue of $0 for fiscal 2025.
What is Quoin Pharmaceuticals' annual revenue history?
Quoin Pharmaceuticals' annual revenue by fiscal year: 2022: $0; 2023: $0; 2024: $0; 2025: $0.
What was Quoin Pharmaceuticals' net income in fiscal 2025?
Quoin Pharmaceuticals reported net income of -$15.8M for fiscal 2025.
What was Quoin Pharmaceuticals' earnings per share (EPS) in fiscal 2025?
Quoin Pharmaceuticals' diluted EPS was -$14.80 for fiscal 2025 (adjusted for any later stock splits).
What was Quoin Pharmaceuticals' revenue last quarter?
In its most recent reported quarter (2026 Q2), Quoin Pharmaceuticals reported revenue of $0.
How many shares of Quoin Pharmaceuticals are outstanding?
Quoin Pharmaceuticals reported a weighted average of 2.8 million basic shares outstanding in 2026 Q2.
What is Quoin Pharmaceuticals' market cap?
Based on its latest closing price, Quoin Pharmaceuticals (QNRX) has a market capitalization of about $11.8M.
Where is Quoin Pharmaceuticals headquartered?
Quoin Pharmaceuticals lists its business address in Ashburn, Virginia in its SEC filings.